Literature DB >> 34529504

Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.

Rebecca L Porter1, Ursula A Matulonis1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34529504      PMCID： PMC8601310          DOI： 10.1200/JCO.21.01886

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  39 in total

1.  Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

Authors:  Jun Zhou; Kathleen M Mahoney; Anita Giobbie-Hurder; Fengmin Zhao; Sandra Lee; Xiaoyun Liao; Scott Rodig; Jingjing Li; Xinqi Wu; Lisa H Butterfield; Matthias Piesche; Michael P Manos; Lauren M Eastman; Glenn Dranoff; Gordon J Freeman; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2017-05-18       Impact factor: 11.151

2.  A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Jeffrey S Weber; Mario Sznol; Ryan J Sullivan; Shauna Blackmon; Genevieve Boland; Harriet M Kluger; Ruth Halaban; Antonietta Bacchiocchi; Paolo A Ascierto; Mariaelena Capone; Carlos Oliveira; Krista Meyer; Julia Grigorieva; Senait G Asmellash; Joanna Roder; Heinrich Roder
Journal:  Cancer Immunol Res       Date:  2017-12-05       Impact factor: 11.151

Review 3.  Regulation of tumor metastasis by myeloid-derived suppressor cells.

Authors:  Thomas Condamine; Indu Ramachandran; Je-In Youn; Dmitry I Gabrilovich
Journal:  Annu Rev Med       Date:  2014-10-09       Impact factor: 13.739

4.  Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.

Authors:  Xia Yuan; Jing Zhang; Dan Li; Ye Mao; Fei Mo; Wei Du; Xuelei Ma
Journal:  Gynecol Oncol       Date:  2017-07-08       Impact factor: 5.482

5.  Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Authors:  U A Matulonis; R Shapira-Frommer; A D Santin; A S Lisyanskaya; S Pignata; I Vergote; F Raspagliesi; G S Sonke; M Birrer; D M Provencher; J Sehouli; N Colombo; A González-Martín; A Oaknin; P B Ottevanger; V Rudaitis; K Katchar; H Wu; S Keefe; J Ruman; J A Ledermann
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

6.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Authors:  Mark Ayers; Jared Lunceford; Michael Nebozhyn; Erin Murphy; Andrey Loboda; David R Kaufman; Andrew Albright; Jonathan D Cheng; S Peter Kang; Veena Shankaran; Sarina A Piha-Paul; Jennifer Yearley; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan
Journal:  J Clin Invest       Date:  2017-06-26       Impact factor: 14.808

Review 7.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

Review 8.  Immune Therapy Opportunities in Ovarian Cancer.

Authors:  Lana E Kandalaft; Kunle Odunsi; George Coukos
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-05

9.  Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Authors:  Kathleen N Moore; Michael Bookman; Jalid Sehouli; Austin Miller; Charles Anderson; Giovanni Scambia; Tashanna Myers; Cagatay Taskiran; Katina Robison; Johanna Mäenpää; Lyndsay Willmott; Nicoletta Colombo; Jessica Thomes-Pepin; Michalis Liontos; Michael A Gold; Yolanda Garcia; Sudarshan K Sharma; Christopher J Darus; Carol Aghajanian; Aikou Okamoto; Xiaohua Wu; Rustem Safin; Fan Wu; Luciana Molinero; Vidya Maiya; Victor K Khor; Yvonne G Lin; Sandro Pignata
Journal:  J Clin Oncol       Date:  2021-04-23       Impact factor: 50.717

Review 10.  Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Xin Luo; Jing Xu; Jianhua Yu; Ping Yi
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561
View more
  6 in total

Review 1.  Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives.

Authors:  Ahmad Awada; Sarfraz Ahmad; Nathalie D McKenzie; Robert W Holloway
Journal:  Onco Targets Ther       Date:  2022-08-10       Impact factor: 4.345

2.  Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.

Authors:  Frank G Lawton; Edward J Pavlik
Journal:  Diagnostics (Basel)       Date:  2022-03-24

3.  Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.

Authors:  Yingchao Zhao; Yao Jiang
Journal:  Onco Targets Ther       Date:  2022-04-02       Impact factor: 4.147

4.  miR-600 promotes ovarian cancer cells stemness, proliferation and metastasis via targeting KLF9.

Authors:  Lili Shan; Pingping Song; Yangyang Zhao; Na An; Yanqiu Xia; Yue Qi; Hongyan Zhao; Jing Ge
Journal:  J Ovarian Res       Date:  2022-05-03       Impact factor: 5.506

5.  Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype.

Authors:  Rebecca L Porter; Siyu Sun; Micayla N Flores; Emily Berzolla; Eunae You; Ildiko E Phillips; Neelima Kc; Niyati Desai; Eric C Tai; Annamaria Szabolcs; Evan R Lang; Amaya Pankaj; Michael J Raabe; Vishal Thapar; Katherine H Xu; Linda T Nieman; Daniel C Rabe; David L Kolin; Elizabeth H Stover; David Pepin; Shannon L Stott; Vikram Deshpande; Joyce F Liu; Alexander Solovyov; Ursula A Matulonis; Benjamin D Greenbaum; David T Ting
Journal:  J Clin Invest       Date:  2022-08-15       Impact factor: 19.456

6.  Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram.

Authors:  Justin W Gorski; Charles S Dietrich; Caeli Davis; Lindsay Erol; Hayley Dietrich; Nicholas J Per; Emily Lenk Ferrell; Anthony B McDowell; McKayla J Riggs; Megan L Hutchcraft; Lauren A Baldwin-Branch; Rachel W Miller; Christopher P DeSimone; Holly H Gallion; Frederick R Ueland; John R van Nagell; Edward J Pavlik
Journal:  Diagnostics (Basel)       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.